NCT00458653|CompletedPhase 1DMC
Loading search results
Sponsor study identifier
interventional
45
2 countries
4
Study Start
April 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
April 2012
Actual (reported)Study Completion
July 2020
Actual (reported)The main purpose of this study is to test the safety and determine the type and severity of any side effects of the Dendritic Cell Fusion Vaccine given in combination with an autologous transplant for patients with multiple myeloma. Autologous stem cell transplantation is a standard therapy for multiple myeloma that is often successful in significantly decreasing the amount of cancer. However, it is not a cure because at some point the multiple myeloma generally begins to grow again. Cancer vaccines are investigational agents that try to stimulate the immune system to recognize and fight against cancer cells. One type of cancer vaccine uses an immune stimulating cell of the body known as a dendritic cell. Research has shown that these dendritic cells can stimulate an immune response against the tumor.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2005
Date type not reportedThis date has not been verified as actual or estimated.
April 10, 2007
Actual (reported)April 11, 2007
Actual (reported)April 2012
Actual (reported)July 2020
Actual (reported)To assess the toxicity associated with vaccination of multiple myeloma patients with dendritic cell/myeloma fusions and GM-CSF prior to stem cell mobilization and following high dose chemotherapy with stem cell rescue.
5 years
To determine whether tumor specific cellular and humoral immunity can be induced by serial vaccination with DC/tumor cell fusions in conjunction with high dose chemotherapy with stem cell rescue
5 years
To determine if vaccination with DC/tumor cell fusions results in clinical disease response in patients with evidence of residual disease post-transplant
5 years
To determine the time to disease progression in this participant population.
Post-transplant vaccination
Pre- and post-transplant vaccination
Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses. Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02114, United States
Dana-Farber Cancer Institute/Brigham & Women's Hospital
Boston, Massachusetts, 02115, United States
Massachusetts General Hospital
Boston, Massachusetts, 02215, United States
Rambam Medical Center
Haifa, 31096, Israel
David Avigan, MD
Beth Israel Deaconess Medical Center
45 participants (actual enrollment reported by the registry).
First Submitted
April 10, 2007
First Posted
April 11, 2007
Study Start
April 2005
Date type not reportedThis date has not been verified as actual or estimated.
Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma
Contact the study team to confirm eligibility.
Primary Completion
April 2012
Actual (reported)Study Completion
July 2020
Actual (reported)Last Updated
June 22, 2023
Record last verified: 2023-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: